We are delighted to inform you about the launch of the 2019 Edgar Stene Prize Competition. At the Opening Plenary Session of the forthcoming European Congress of Rheumatology in Madrid, Spain, on 12 June 2019, the Edgar Stene Prize will be awarded to the winning essay on the topic:

“My ideal employer – Work without barriers for people with RMDs”

EULAR invites people with RMDs to write about their personal experiences. We all want to live life to the fullest and independently and work is an essential part of our life. Be it paid work, voluntary work or looking after the family and a household, this can be a challenge for people with RMDs. What measures, aids, attitudes by employers – this can also be the family, society or the organisation or institution you would like to volunteer for – can support people with RMDs to be able to work in their dream job, or look after a family – we want to hear from you this year what should your ideal employer offer to you to make your work more accessible and manageable – or if there is already something which is reality we want to hear your best practice examples!

As in the past, we encourage our national EULAR member organisations of PARE to organise national competitions for people with a rheumatic or musculoskeletal disease (minimum 18 years of age). Competitors should be invited to submit an essay not exceeding 2 pages (A4) in their own language to their national EULAR member organisation of PARE. The deadline for the national completion will be set individually by each national organisation. Anyone who would like to submit an essay should get in touch with their respective national EULAR member organisation for further information.

Each national jury should select and submit the best entry from their country (only one entry) by email to the EULAR Secretariat by 20 January 2019. A more detailed outline of the rules can be obtained by contacting the EULAR secretariat. Please note that these have to be fully adhered to, as applications which are not complete will not be accepted by the EULAR Secretariat.

A EULAR Jury will select the 2019 Stene Prize winner to be announced by 15 March 2019. The jury’s decision is incontestable. Information about the 2019 EULAR Jury will be posted in the coming months on www.eular.org

The Stene Prize winner will be invited to attend the Opening Plenary Session of the EULAR Congress in Madrid and is awarded a prize of € 1 000. EULAR provides the winner with travel to Madrid and hotel accommodation for up to 4 nights as well as with
an invitation to the EULAR Congress Gala Dinner. The second ranking essay will be awarded with € 700 and the third ranking essay with € 300.

Thank you so much in advance for supporting this exciting and important competition in your country. If we can help with any questions please do not hesitate to contact the EULAR secretariat. The 2019 Edgar Stene Prize Jury looks forward to receiving many
entries from all over Europe!

With kindest regards,

Nele Caeyers, Chair, EULAR Standing Committee of PARE
Dieter Wiek, Vice President, EULAR, representing PARE
Polina Pchelnikova, PARE Working Group Leader Edgar Stene Prize

rgb_eular_stene-prize_logo_2019

Live Facebook Feed

Comments Box SVG iconsUsed for the like, share, comment, and reaction icons
1 week ago
LUPUS EUROPE

🚨 Call for patients🚨

🔊 INSPIRE SURVEY from the University of Cambridge.

This survey aims to improve the understanding of neurological symptoms in SLE and other rheumatic conditions.

Lupus is a very heterogeneous disease, which means that it affects people of different ethnic backgrounds and gender in different ways.

That is why, to get accurate research results, as many different groups as possible must be represented in the sample.

The INSPIRE survey was launched last year to get the patient experience on the assessment/monitoring of neurological symptoms, but they received very few responses from people from ethnic minorities.

That is why the research team led by Dr Chris Wincup has launched a new survey.

The new INSPIRE survey can be completed by lupus patients or their carers from around the world.

🟣 Please share as much as possible 🟣 in order to get a sample that includes a good proportion of all ethnic groups.

Thank you!

bit.ly/inspire_patients_short
... See MoreSee Less

Comment on Facebook

I did it a second time and no it went good till the end

The survey was demolished.

1 week ago
LUPUS EUROPE

Discoid lupus erythematosus (DLE) is the most common form of chronic cutaneous lupus erythematosus. It is characterised by persistent scaly plaques on the scalp, face, and ears, which can progress to scarring, atrophy, depigmentation, and permanent hair loss in affected hair-bearing areas (Source: DermNet).

This study, published by Prof Marca Mosca et al., describes 2 cases of severe and refractory DLE successfully treated with anifrolumab, a human monoclonal antibody.

Although anifrolumab has been recently approved for the treatment of SLE, data from randomized clinical trials have shown a significant difference in cutaneous response rate in patients treated with anifrolumab from those in the placebo group.

While the effectiveness of this treatment in real life and in different types of skin lesions has yet to be determined, it could represent a new valid opportunity for treating DLE.

jamanetwork.com/journals/jamadermatology/article-abstract/2798967
... See MoreSee Less

Discoid lupus erythematosus (DLE) is the most common form of chronic cutaneous lupus erythematosus. It is characterised by persistent scaly plaques on the scalp, face, and ears, which can progress to scarring, atrophy, depigmentation, and permanent hair loss in affected hair-bearing areas (Source: DermNet). 

This study, published by Prof Marca Mosca et al., describes 2 cases of severe and refractory DLE successfully treated with anifrolumab, a human monoclonal antibody. 

Although anifrolumab has been recently approved for the treatment of SLE, data from randomized clinical trials have shown a significant difference in cutaneous response rate in patients treated with anifrolumab from those in the placebo group. 

While the effectiveness of this treatment in real life and in different types of skin lesions has yet to be determined, it could represent a new valid opportunity for treating DLE.

https://jamanetwork.com/journals/jamadermatology/article-abstract/2798967Image attachmentImage attachment
1 week ago
LUPUS EUROPE

We know some of you missed the great seminar recently delivered by Prof. Laurent Arnaud.

Well, no worries!

You have the chance to see it again, thanks to the European Federation of Internal Medicine (EFIM).

"Challenges in 2023 for Systemic Lupus Erythematosus".

Next 29th of March at 18:00 CET (i.e. Paris time).

Register for free here!

us02web.zoom.us/webinar/register/WN_O5yMwjfgTS29pMKvOZfgZw
... See MoreSee Less

We know some of you missed the great seminar recently delivered by Prof. Laurent Arnaud. 

Well, no worries! 

You have the chance to see it again, thanks to the European Federation of Internal Medicine (EFIM). 

Challenges in 2023 for Systemic Lupus Erythematosus.

Next 29th of March at 18:00 CET (i.e. Paris time).

Register for free here! 

https://us02web.zoom.us/webinar/register/WN_O5yMwjfgTS29pMKvOZfgZwImage attachment
1 week ago
LUPUS EUROPE

Did you miss this ERN RECONNET webinar with Lou Kawka and Prof Laurent Arnaud about #fatigue in #SLE?

Now you have the chance to watch it!!! 😃🙌

www.youtube.com/watch?v=7jc7SiP5BsA
... See MoreSee Less

Did you miss this ERN RECONNET webinar with Lou Kawka and Prof Laurent Arnaud about #fatigue in #SLE? 

Now you have the chance to watch it!!! 😃🙌

https://www.youtube.com/watch?v=7jc7SiP5BsA
LUPUS EUROPE Uniting people with Lupus throughout Europe
Send